Celecoxib/tramadol

Celecoxib/tramadol

Combination of
Celecoxib	Nonsteroidal anti-inflammatory drug (NSAID)
Tramadol hydrochloride	Opioid agonist
Clinical data
Trade names	Seglentis
Other names	E-58425
License data	US  DailyMed:  Celecoxib_and_tramadol
Routes of administration	By mouth
ATC code	N02AJ16 ( WHO )
Legal status
Legal status	US: Schedule IV [1]
Identifiers
KEGG	D12491

Celecoxib/tramadol sold under the brand name Seglentis, is a fixed-dose combination of the anti-inflammatory celecoxib and the opioid tramadol used for the management and treatment of pain. ^[1]

Developed by Spanish pharmaceutical company Esteve, it was approved for medical use in the United States in October 2021. ^{[1] [2] [3]}

References

1. "Seglentis- celecoxib and tramadol hydrochloride tablet". DailyMed. Retrieved 8 January 2022.
2. "Seglentis: FDA-Approved Drugs". U.S. Food and Drug Administration. Archived from the original on 19 October 2021. Retrieved 18 October 2021.
3. "Esteve Announces FDA Approval Of A Novel Co-Crystal Form Of Celecoxib And Tramadol For The Management Of Acute Pain". Esteve (Press release). 15 October 2021. Retrieved 18 October 2021.

External links

• "Celecoxib". Drug Information Portal. U.S. National Library of Medicine.
• "Tramadol hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
• Clinical trial number NCT03108482 for "Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial." at ClinicalTrials.gov